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Abstract
Purpose—The 34-gene classifier, ClearCode34, identifies prognostically distinct molecular 
subtypes of clear cell renal cell carcinoma (ccRCC) termed ccA and ccB. The primary objective of 
this study was to describe clinical characteristics and comorbidities of relevance in patients 
stratified by ClearCode34.
Patients and Methods—In this retrospective analysis, 282 patients from Moffitt Cancer Center 
with ccRCC with gene expression analyses of the primary tumor were identified and ClearCode34 
was applied to identify tumors as ccA or ccB. The medical record and institutional databases were 
queried to define patient characteristics, comorbidities, and outcomes.
Results—We validated in this external cohort the superior overall survival (OS), cancer specific 
survival (CSS), and recurrence-free survival of ccA patients relative to ccB patients (p<0.001). 
Addressing other clinical characteristics, the ccA patients were more likely to be obese (48% 
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versus 34%, p=0.021) and diabetic (26% versus 13%, p=0.035). The ccA patients also trended 
towards having been more frequent users of angiotensin system inhibitors (ASIs) (71% versus 
52%, p=0.055). In multivariate analyses, ccB status is independently associated with inferior CSS 
(HR 3.26, 95% CI 1.84–5.79) and OS (HR 2.50, 95% CI 1.53–4.08).
Conclusions—ClearCode34, after considering distinct patterns of comorbidities in each 
molecular subtype, remains a strong prognostic tool in ccRCC patients. Obesity and DM emerged 
as factors that may influence ccRCC phenotypes and further studies investigating the impact of 
these metabolic conditions functionally onto tumor biology are warranted. Additionally, use of 
ASI could be studied in the context of ccRCC molecular classification in future studies to better 
understand its impact on ccRCC outcomes.
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ClearCode34; clear cell renal cell carcinoma; obesity; diabetes mellitus
1. Introduction
Cancers of the kidney and renal pelvis are among the more common cancers diagnosed in 
the United States with an estimated 61,560 new cases and 14,080 deaths for 2015 [1]. In 
adults, the overwhelming majority of these cases were renal cell carcinoma (RCC). 
Significant effort has been expended in developing ways to stratify RCC patients into 
clinically meaningful categories in order to inform clinical decisions. Classically, anatomical 
features (e.g. TNM classification or Fuhrman nuclear grade) were used to predict more 
aggressive disease [2]. Clinical prognostic systems are commonly used and include both 
clinical factors and laboratory data [3, 4]. Models including molecular testing have also 
received much attention in the prognostication of RCC, including multi-gene expression 
signatures [5–7]. The most comprehensive molecular analysis to date of clear cell RCC 
(ccRCC), the most common RCC histologic subtype, was The Cancer Genome Atlas 
(TCGA) study. The TCGA group analyzed over 400 tumors on multiple platforms and 
described numerous molecular changes that correlated significantly with patient outcomes 
[8]. However, despite these intense efforts, no models using molecular analyses are routinely 
utilized in the clinic to direct patient care.
Brannon et al. and others used gene expression microarrays to describe two dominant 
molecular subtypes of ccRCC tumors termed clear cell A (ccA) and clear cell B (ccB) [6, 8, 
9]. The ccA patients demonstrated superior overall survival (OS), cancer-specific survival 
(CSS), and recurrence free survival (RFS) [6, 7]. However, these studies, in utilizing frozen 
tissue and large numbers of gene probes, have significant barriers to translational and 
clinical applications. Brooks et al. published a method that attempts to circumvent these 
barriers [7]. In their work, a model using 34 genes (coined ClearCode34) was developed that 
reliably classified individual tumors as ccA and ccB from formalin-fixed, paraffin embedded 
tumor specimens (Table 1). Prognostic models containing this signature outperformed 
traditional clinical nomograms [7]. Thus, ClearCode34 is poised for further study in readily 
available specimens.
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While new technology will facilitate translational investigations, much remains to be learned 
regarding the patients who constitute the ccA and ccB cohorts. Some clinical annotation has 
previously been described, such as lower stage and Fuhrman nuclear grade among ccA 
patients [6]. However, further clinical description, for example the anatomic metastatic 
pattern, of these patient cohorts is lacking. Furthermore, while evidence emerges that 
comorbidities and their treatment may influence kidney cancer outcomes [10, 11], the 
distribution of these among ccA and ccB patients remain to be addressed. These are analyses 
which may prove important in understanding the biology and clinical relevance of these 
ccRCC molecular subtypes.
2. Patients and methods
2.1. Patients and clinical samples
Gene expression data was obtained from primary ccRCC tumors of patients treated with 
nephrectomy at Moffitt Cancer Center (MCC) from 1/1/1998 to 10/25/2011 and organized 
through the Total Cancer Care (TCC) initiative [12]. Priority was given to samples with 
sufficient quantity to satisfy both clinical and research requirements. Tissue was collected 
and snap frozen within 15 minutes of surgical extirpation with cold ischemia times typically 
<5 minutes. Subsequently, frozen sections were prepared and stained. In order to be eligible 
for molecular analysis, tissue was evaluated by TCC pathologists for quality control and 
central pathology review. Macro-dissection was performed in liquid nitrogen to maintain the 
frozen tissue and enrich tumor. RNA extraction was performed and specimens arrayed on 
Affymetrix HuRSTA-2a520709 GeneChips (Affymetrix, Santa Clara, CA) chips with over 
60,000 probe sets representing over 22,000 unique genes. Further details on the MCC TCC 
initiative and protocol were previously published [12]. Inclusion criteria included adult 
patients (>18 years old) with ccRCC. A total of 282 ccRCC primary tumors with gene 
expression data in TCC were identified; follow-up data including survival and vital status 
were obtained as part of the TCC initiative. Median follow-up was 74 months for all patients 
(74 for ccA and 76 for ccB). Patients’ medical records were reviewed to further define study 
variables. Clinical characteristics such as age, BMI [weight (kg)/height2 (m2)], and 
comorbidity status and treatment were gathered at time of diagnosis. A patient was classified 
as obese if BMI was 30 kg/m2 or greater. Patients were considered to have hypertension, 
hyperlipidemia, or diabetes mellitus (DM) if they reported use of a medication typically 
used to treat the condition. All samples and data were obtained with appropriate institutional 
review board approvals.
2.2. Application of gene expression classifier of ccA or ccB
The ClearCode34 consists of a 34 gene panel (Table 1) that was previously published [7] 
and assigns tumors as either ccA or ccB according to gene expression level. Tumor 
classification was performed in R program (www.r-project.org) using Prediction Analysis of 
Microarrays for R (PAMR), a centroid-based classification algorithm [7].
2.3. Statistical analysis
All continuous variables were described with the median and range values. OS was defined 
as the time from diagnosis to death of any cause. CSS was defined as the time from 
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diagnosis to death from ccRCC; patients who remained alive, died of other causes, or had 
unknown cause of death were censored at the time of last follow-up or death. RFS was 
defined as the date from nephrectomy to the earliest date that recurrence or metastasis was 
described by imaging or pathology report. The probability of death or recurrence was 
determined by using the Kaplan-Meier method, and comparisons were performed using a 
log-rank test. Significance of categorical analyses was determined with two-tail Fisher’s 
exact test (two variables) or chi-squared (three variables). Significance of medians was 
evaluated with Mann-Whitney U test. Cox regression multivariate analyses were performed 
with SPSS version 21.
3. Results
3.1. Patient characteristics of molecular subtypes
Of the 282 ccRCC tumors studied, 226 (80%) were classified as ccA and the remainder as 
ccB (Table 2). Univariate analyses (UVAs) demonstrated that ccA patients, relative to ccB 
patients, presented with lower Fuhrman nuclear grade (p<0.001) and smaller tumors (median 
4.6 cm versus 7.2 cm, p=0.003) and were less likely to have nodal involvement (4% versus 
11%, p=0.038) or metastatic disease (23% versus 60%, p=0.003). There were no statistically 
significant distinctions in anatomic pattern of metastastic spread between the ccA and ccB 
patients: lung-only (19% versus 31%, p=0.201), lung (79% versus 63%, p=0.130), bone 
(45% versus 45%, p=1.000), brain (21% versus 13%, p=0.393), and liver (9% versus 13%, 
p=0.723).
3.2. Overall survival, cancer specific survival, and recurrence-free survival of molecular 
subtypes
Consistent with prior publications, the ccB patients demonstrated inferior OS relative to ccA 
patients (median OS 151 months versus 31 months, log-rank p<0.001) with a hazard ratio 
(HR) of 5.52 (95% CI, 3.17–9.61) (Fig. 1a) as well as inferior CSS (median CSS 253 versus 
33 months, p<0.001) with a HR of 12.45 (95% CI, 6.45–24.03) (Fig. 1b). The ccB patients 
were also inferior for recurrence-free survival (RFS) in non-metastatic patients after 
nephrectomy (median not reached, p<0.001) with a HR of 12.20 (95% CI, 4.48–33.17) (Fig. 
1c).
3.3. Comorbidities in relationship to ClearCode34 subtypes
There is a growing appreciation for the impact of comorbidities, such as hypertension and 
hyperlipidemia, and their treatment on RCC outcomes. Therefore, we sought to evaluate 
whether comorbidities and their treatments at time of diagnosis contribute to the divergent 
outcomes observed for the ClearCode34 subtypes. Intriguingly, the ccA patients have a 
higher median BMI at diagnosis relative to the ccB patients (29.7 versus 27.7, p=0.019) and 
a higher frequency of obesity (48% versus 34%, p=0.021; Table 3). In addition, there was a 
higher rate of DM among ccA patients relative to ccB patients (26% versus 13%, p=0.035). 
The risk of RCC in patients with hypertension has been observed to be related to the degree 
of hypertension [13–16]. However, similar rate of hypertension was observed in each 
subtype (63% versus 56%, p=0.355) though there was a trend towards increased utilization 
of ASI among the ccA patients with hypertension (71% versus 52%, p=0.055). Similar rates 
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of hyperlipidemia and statin utilization were observed. Despite being associated with 
advanced RCC [17], smoking rates were similar in each subtype (Table 3).
3.4. Univariate and multivariate Cox proportional hazards regression for cancer-specific 
survival and overall survival
While prior work showed ccA patients have a lower stage and grade of disease, the current 
study also identified a higher BMI and rate of obesity, higher rate of DM, and of a trend 
towards increased utilization of ASIs in the ccA patients. As BMI and ASI use are reported 
to be associated with improved outcomes in kidney cancer, we sought to determine whether 
comorbidities and their treatment were confounding the survival analyses for ClearCode34 
subtypes and could thus explain the improved outcomes seen in ccA patients. UVA and 
multivariate analysis (MVA) using the Cox regression model for OS and CSS included these 
novel variables (BMI, DM status, ASI utilization) as well as established variables (age, 
grade, tumor size, nodal status, metastatic disease; Tables 4 and 5). In the CSS analysis, ccB 
status was associated with inferior survival relative to ccA patients in both UVA and MVA 
(UVA: p<0.001; HR 5.01, 95% CI 3.14–8.00 and MVA: p<0.001; HR 3.26, 95% CI 1.84–
5.79). Similarly, in the OS analysis, ccB status was also associated with inferior survival in 
both UVA and MVA (UVA: p<0.001; HR 3.23, 95% CI 2.16–4.86 and MVA: p<0.001; HR 
2.50, 95% CI 1.53–4.08). Among the novel variables, the UVA showed DM was not 
associated with survival, neither for CSS (p=0.125, HR 0.84, 95% CI 0.47–1.51) nor for OS 
(p=0.484; HR 1.17, 95% CI 0.75–1.83). However, in the MVA, DM was associated with 
inferior CSS (p=0.011; HR 2.56, 95% CI 1.24–5.30) and inferior OS (p=0.001; HR 2.43, 
95% CI 1.41–4.18). The use of ASI was not associated with survival in any of these 
analyses.
4. Discussion
This large, single-institution, retrospective study validated the prognostic significance of the 
ClearCode34 subtypes ccA and ccB in an independent cohort of ccRCC patients. In 
addition, we provide a novel description of the clinical characteristics of the patients that 
constitute these ccRCC subtypes. The ccA patients are more likely to be obese and diabetic. 
The ccB patients have an inferior prognosis, larger tumors, higher Fuhrman nuclear grade, 
increased nodal involvement, and are more likely to have tumor that is or becomes 
metastatic. Importantly, multivariate analyses for both OS and CSS demonstrate that even 
after considering factors such as tumor size, grade, and comorbidities, ccA/ccB distinction 
makes a significant and robust contribution to survival models. This work reinforces the 
concept that ccA and ccB defines distinct clinical cohorts with unique tumor biology.
In the current study, the prognostically superior ccA group has a higher rate of obesity while 
the ccB patients have a rate of obesity similar to other Americans of a similar age (Table 3) 
[18]. This observation highlights a paradox involving BMI and ccRCC. Obesity is a risk 
factor for RCC in both men and women [19] yet obese RCC patients have lower stage 
disease, improved survival, and improved outcomes when treated with targeted therapies 
relative to non-obese patients [20, 21]. Thus, our observation that ccA patients, with a higher 
BMI and rate of obesity, have superior outcomes is consistent with those observations. 
However, this retrospective data is not sufficient to conclude that obesity directly causes 
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development of ccA tumors. Future studies should further explore how obesity impacts 
kidney tumor biology and how best to exploit this unique biology for the benefit of patients.
Increased incidence of solid tumors has long been recognized in patients with DM [22]. 
However, DM as a risk factor for RCC, and its impact on RCC outcomes, is controversial 
[23–25]. In the current study, ccA patients had increased incidence of DM at time of 
diagnosis relative to ccB patients. Interestingly, in MVA, DM was associated in inferior 
CSS and OS despite being associated with the superior prognostic group, ccA. Despite this 
conundrum, the prognostic validity of ClearCode34 persists as ccA status continues to 
correlate with improved CSS and OS in MVA that included DM. Given the increased 
incidence of obesity and DM in ccA patients, the question of whether host features can 
impact molecular subtypes and tumor biology is raised. Future, ideally prospective studies, 
are needed to address this question further.
As ccA patients are more likely to have DM, it is not surprising that a trend was observed 
towards increased ASI use in ccA patients (71% of ccA patients versus 52% of ccB patients, 
p=0.055). Due to their proven benefit, guidelines for therapy of DM list multiple indications 
for ASIs in DM patients, including hypertension [26]. The current study did not support a 
protective effect for ASI in ccRCC (Tables 4 and 5). However, other studies have found that 
ASIs may offer survival benefits in kidney cancer in the targeted treatment era [11, 27]. 
Possibilities for this discrepancy include insufficient power in the current study to detect a 
benefit from ASIs. Another possibility is that ClearCode34 status was confounding the 
results of the other studies since ccA patients, a group with superior survival, may have 
increased rates of DM and ASI use. Thus, the benefit from ASI seen in other studies may 
have been partly due to an enrichment of ccA patients among ASI users. Further, ideally 
prospective, studies are needed to resolve this uncertainty regarding the benefits of ASIs in 
kidney cancer patients.
Limitations of the current study include the sample size as well as the retrospective nature of 
the study. In addition, the study period was long in order to maximize sample size. A 
prospective cohort study would better capture details of comorbidities in patients during the 
time of tumorigenesis (i.e. years prior to diagnosis of kidney cancer) but would require a 
very large sample size. Given practice patterns, the MCC electronic medical record lacks 
some data that would further illuminate the questions raised in the current study regarding 
comorbidities (e.g. hemoglobin A1C values). In addition, we identified more ccA tumors 
than ccB. While other studies too have observed a greater incidence of ccA relative to ccB 
[6, 8, 9], we cannot exclude unintended bias impacting selection of which patients go to 
surgery and which tumors get selected for study. Finally, heterogeneity within tumors has 
been documented for gene expression profiles (GEPs) [28]. Whether a scoring system 
integrating ClearCode34 classification from multiple sites of the primary tumor, or other 
strategies to capture the heterogeneity of an individual tumor, would impact the prognostic 
ability of this GEP is an important question going forward.
This work validates, in an external dataset, the ability of ClearCode34 to provide prognostic 
information in ccRCC [7]. The increased prevalence of obesity and DM in the ccA patients 
raises the question of whether comorbidities influence tumor biology and predispose to the 
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development of a particular molecular subtype, or could, conversely, provide a protective 
effect that hinders disease progression. In addition, it is interesting that in the current MVAs, 
DM status is associated with inferior survival. While this observation requires validation, if 
true, the mechanism of this effect becomes an important research question with possibilities 
including tumor-promoting changes in the tumor microenvironment (i.e. diabetic 
nephropathy) versus a potential DM-associated metabolic effect. Furthermore, while other 
studies have demonstrated improved survival in RCC with ASI use, the current study fails to 
observe such effect. Since ASI users may enrich for prognostically superior ccA patients, 
this is a potential source of bias and thus ClearCode34 status may enhance future studies 
evaluating ASI benefit in ccRCC.
5. Conclusion
ClearCode34 identifies biologically-divergent molecular subtypes of kidney cancer that 
originates in patients with distinct comorbidities.
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Highlights
• ClearCode34 subtypes clear cell RCC tumors in molecular subtypes, ccA and 
ccB
• ccA patients have higher rate of obesity and diabetes mellitus
• After considering host comorbidities, ccA patients remain prognostically 
superior
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Figure 1. ClearCode34 defines ccRCC subtypes with significantly different patient outcomes
The ccA patients had superior a) overall survival, b) cancer-specific survival and c) 
recurrence free survival relative to ccB patients.
Haake et al. Page 10
Urol Oncol. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Haake et al. Page 11
Table 1
ClearCode34 Gene Expression Profile
ccA ccB
ARNT NRP1 CCNO
BNIP3L PDGFD FLJ23867
C11orf1 PHYH FOXM1
CDH5 PRKAA2 GALNT10
EHBP1 RGS5 GALNT4
EPAS1 SLC4A4 KCNN4
ESD SPRYD7 MOXD1
FZD1 ST13 ROR2
GIPC2 STK32B SERPINA3
LEPROTL1 TCEA3 SLC4A3
MAOB TLR3
MAPT VCAM1
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